Drug

View All

Cost ineffective Orphan Drugs limit the access

Rare diseases are mostly serious, chronic and life-threatening, associated with both psychological as well as financial burdens. In addition, only a few of them have effective drug treatment available. The European Union (EU) definition of a rare disease is one that affects fewer than 5 in 10,000 people. These affe...

Find More

Delveinsight
A promising immune-stimulating target

For over 100 years, immunotherapy has played a significant role in the treatment of cancer. Immune stimulatory agents such as Toll-like receptor (TLR) agonists, adoptive T cell and natural killer (NK) cell therapies, cytokine-based therapies etc. have gained approval for treatment of various indications. In 1980s, r...

Find More

Delveinsight
Anticoagulants (VTE & AF) Therapeutics Market

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Antico...

Find More

Delveinsight
Global atrial fibrillation market is expected to grow to $12.5 billion by 2020

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa. DelveInsight Atrial Fibrillation-Market Insights & Drugs ...

Find More

Delveinsight
Global VTE market is expected to grow to $4.75 billion by 2020

Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020: New Report by DelveInsight suggests that the Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%. DelveInsight Report “Venous Thromboembolism-Market ...

Find More

Delveinsight
Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2020

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...

Find More

Delveinsight
Non-Hodgkin’s Lymphoma (NHL) – Market Insights, Epidemiology and Market Forecast-2020

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...

Find More

Delveinsight
Nonalcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology and Market Forecast-2020

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. Del...

Find More

Delveinsight
PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016

DelveInsight has made strong presence in Oncology market with 100+ Reports on Oncology based Indications & Mechanism of Action (MOA). DelveInsight Report, PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 has received great response and feedback from clients. PD-1and PDL-1 is...

Find More

Delveinsight
LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise pro...

Find More